- Home
- BIVI
BIVI
BioVie Inc.
as 06-06-2025 4:00pm EST
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CARSON CITY |
| Market Cap: | 18.6M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 282.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $7.50 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioVie Inc. News
BIVI Breaking Stock News: Dive into BIVI Ticker-Specific Updates for Smart Investing
ACCESS Newswire
21 days ago
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
22 days ago
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
GlobeNewswire
23 days ago
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
GlobeNewswire
a month ago
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
GlobeNewswire
a month ago
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
ACCESS Newswire
a month ago
New to The Street Airs on Bloomberg TV Saturday, April 26 at 6:30 PM ET Featuring BioVie (NASDAQ: BIVI), Skip Barber Racing School with CFO Michael Berg, CommercialVille.tv, Sustainable Green Team (OTCPK: SGTM) WaterLess Garden, and The Business of Blockchain with Michael Casey
GlobeNewswire
2 months ago
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
ACCESS Newswire
2 months ago
New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), and ARRIVE AI Founder & CEO Dan O'Toole (ARAI)
Compare BIVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIVI BioVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.